Buy Rating Affirmed for Keros Therapeutics: Promising Pipeline and Strong Financial Health

Keros Therapeutics (KROS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tiago Fauth from Wells Fargo maintained a Buy rating on the stock and has a $88.00 price target.

Tiago Fauth has given his Buy rating due to a combination of factors including the strong potential of Keros Therapeutics’ pipeline and the company’s solid financial health. The focus remains on the differentiation story of KER-012 and the potential of KER-065 in tackling obesity. The upcoming data from the Phase 2 open-label biomarker trial in chronic heart failure patients is anticipated to be a key driver for the stock in the second half of 2024. Additionally, Fauth’s valuation reflects investor interest, particularly in KER-065 as a unique approach to obesity treatment, and KER-012’s potential for use in pulmonary arterial hypertension (PAH).
Furthermore, Keros Therapeutics’ financial position, with approximately $442 million in cash expected to fund operations into 2027, provides a stable foundation for the company’s progress. The engagement with regulators on the Phase 3 trial design for KER-050 in myelodysplastic syndromes (MDS), and the anticipated updates in mid-2024 are also seen as positive indicators. The company’s progress in enrolling patients for the Phase 2 TROPOS trial and the expected data release in 2025 bolster the optimistic outlook for Keros Therapeutics’ stock, supporting Fauth’s Buy rating.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Keros Therapeutics (KROS) Company Description:

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company’s protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.